Seroprevalence of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers in Makkah, Saudi Arabia

• Published in: Journal of King Saud University. Science 2021-05, Vol.33 (3), p.101366-101366, Article 101366
• Main Authors: Ahmed, Waleed A., Dada, Ashraf, Alshukairi, Abeer N., Sohrab, Sayed S., Faizo, Arwa A., Tolah, Ahmed M., El-Kafrawy, Sherif A., Bajrai, Leena H., Moalim, Hanan M., Aly, Mohamed H., Aboelazm, Ahmed F., Al-Hamzi, Mohammed A., Saeedi, Mohammed F., Alandijany, Thamir A., Azhar, Esam I.
• Format: Article
• Language: English
• Subjects: COVID-19; Healthcare workers; Original; SARS-CoV-2; Saudi Arabia; Seroprevalence
• ISSN: 1018-3647; 2213-686X
• DOI: 10.1016/j.jksus.2021.101366

The new coronavirus disease 2019 (COVID-19) is a major health problem worldwide. The surveillance of seropositive individuals serves as an indicator to the extent of infection spread and provides an estimation of herd immunity status among population. Reports from different countries investigated this issue among healthcare workers (HCWs) who are “at risk” and “sources of risk” for COVID-19. This study aims to investigate the seroprevalence of COVID-19 among HCWs in one of the COVID-19 referral centers in Makkah, Saudi Arabia using three different serological methods. In-house developed enzyme-linked immunoassay (ELISA), commercially available electro-chemiluminescence immunoassay (ECLIA), and microneutralization (MN) assay were utilized to determine the seroprevalence rate among the study population. 204 HCWs participated in the study. Both physicians and nurses working in the COVID-19 and non COVID-19 areas were included. Twelve out of 204 were confirmed cases of COVID-19 with variable disease severity. Samples from recovered HCWs were collected four weeks post diagnosis. The overall seroprevalence rate was 6.3% (13 out of 204) using the in-house ELISA and MN assay and it was 5.8% (12 out of 204) using the commercial ECLIA. Among HCWs undiagnosed with COVID-19, the seroprevalence was 2% (4 out 192). Notably, neutralizing antibodies were not detected in 3 (25%) out 12 confirmed cases of COVID-19. Our study, similar to the recent national multi-center study, showed a low seroprevalence of SARS-Cov-2 antibodies among HCWs. Concordance of results between the commercial electro-chemiluminescence immunoassay (ECLIA), in-house ELISA and MN assay was observed. The in-house ELISA is a promising tool for the serological diagnosis of SARS-CoV-2 infection. However, seroprevalence studies may underestimate the extent of COVID-19 infection as some cases with mild disease did not have detectable antibody responses.